Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?
Christopher D. Lao, Nikhil I. Khushalani, Christina V. Angeles, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 738-744
Open Access | Times Cited: 25

Showing 25 citing articles:

Bridging the gap between testing and clinics exploring alternative pre-clinical models in melanoma research
Juliana Santos Rosa Viegas, Bruno Sarmento
Advanced Drug Delivery Reviews (2024) Vol. 208, pp. 115295-115295
Open Access | Times Cited: 12
Open-Label, Phase II Study of Talimogene Laherparepvec Plus Pembrolizumab for the Treatment of Advanced Melanoma That Progressed on Prior Anti–PD-1 Therapy: MASTERKEY-115,
Caroline Robert, Brian Gastman, Helen Gogas, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114120-114120
Closed Access | Times Cited: 9
Advances in targeted therapy and immunotherapy for melanoma (Review)
Ziyao Qin, Mei Zheng
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 16
Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
Hildur Helgadóttir, Lars Ny, Gustav Ullenhag, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 9, pp. 1077-1084
Open Access | Times Cited: 14
Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations
Walid Shalata, Zoé Gabrielle Attal, Adam Solomon, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5794-5794
Open Access | Times Cited: 5
Environment-responsive dendrobium polysaccharide hydrogel embedding manganese microsphere as a post-operative adjuvant to boost cascaded immune cycle against melanoma
Nan Gao, Yiran Huang, Shisuo Jing, et al.
Theranostics (2024) Vol. 14, Iss. 10, pp. 3810-3826
Open Access | Times Cited: 4
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Mahrukh M. Syeda, Georgina V Long, James H. Garrett, et al.
The Lancet Oncology (2025)
Closed Access
Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment
Piotr Rutkowski, Mario Mandalà
European Journal of Surgical Oncology (2024) Vol. 50, Iss. 3, pp. 107969-107969
Closed Access | Times Cited: 3
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4142-4142
Open Access | Times Cited: 14
Therapeutic potential of marine peptides in malignant melanoma
Salman Ahmed, Waqas Alam, Khalaf F. Alsharif, et al.
Environmental Research (2023) Vol. 227, pp. 115771-115771
Closed Access | Times Cited: 7
Patterns of Recurrence of Cutaneous Melanoma: A Literature Review
Dominga Peirano, Francisca Donoso, Sebastián Vargas, et al.
Dermatology Practical & Conceptual (2023), pp. e2023304-e2023304
Open Access | Times Cited: 7
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience
Francesca Romana Di Pietro, Daniele Marinelli, Sofia Verkhovskaia, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
Joanna Placzke, Magdalena Rosińska, Paweł Sobczuk, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4384-4384
Open Access | Times Cited: 6
Treatment management forBRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Maximilian Haist, Henner Stege, Friederike Rogall, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 9, pp. e007630-e007630
Open Access | Times Cited: 6
Adjuvant immune checkpoint blockade revisited
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Atse H Huisman, Anke Pisters-van Roy, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. 717-719
Closed Access | Times Cited: 4
Immune-related [18F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications
Giulia Santo, Maria Cucè, Antonino Restuccia, et al.
Cancer Imaging (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Germline mechanisms of immunotherapy toxicities in the era of genome‐wide association studies
Alexander Gusev
Immunological Reviews (2023) Vol. 318, Iss. 1, pp. 138-156
Closed Access | Times Cited: 2
Co-Targeting Nucleus Accumbens Associate 1 and NF-κB Signaling Synergistically Inhibits Melanoma Growth
Lixiang Gu, Xingcong Ren, Chrispus Ngule, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2221-2221
Open Access | Times Cited: 2
Immune Checkpoint Inhibitors in Oncology
Katherine A. Smith, Svetomir N. Markovic
Springer eBooks (2024), pp. 11-23
Closed Access
Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US
Eric D. Whitman, Todor Totev, Shan Jiang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry
Loeki Aldenhoven, Merel A. Spiekerman van Weezelenburg, Franchette W.P.J. van den Berkmortel, et al.
Targeted Oncology (2024) Vol. 19, Iss. 5, pp. 735-745
Open Access
The economic burden of recurrence in elderly patients with completely resected, stage IIB/IIC or III melanoma: an analysis of the Surveillance, Epidemiology, and End Results-Medicare linked database
Ruixuan Jiang, Travis Wang, Yue Liu, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 1279-1292
Open Access
Diabetic Ketoacidosis as a Debut and Immune-Mediated Complication Caused by Pembrolizumab: Case Report
Julian Andrés Pacichana, Luis Miguel Osorio-Toro, Katherine Restrepo, et al.
Diabetology (2024) Vol. 5, Iss. 6, pp. 600-607
Open Access
Patterns of systemic treatment for melanoma: an insight on trends and costs between 2019–2023 from the English systemic anti-cancer therapy national database
Tommaso Bosetti, Oliver John Kennedy, Rebecca Lee, et al.
EJC Skin Cancer (2024), pp. 100279-100279
Open Access
ASO Author Reflections: The Clinical Relevance of Sentinel Nodes in Minor Lymph Node Fields Such as the Triangular Intermuscular Space in Patients with Melanoma
Trine Schoenfeldt, Annette H. Chakera, Omgo E. Nieweg, et al.
Annals of Surgical Oncology (2023) Vol. 30, Iss. 9, pp. 5770-5771
Open Access
Page 1

Scroll to top